European Primary Care Cardiovascular Society

Diabetes

Diabetes is now considered an important risk factor for cardiovascular disease, and a complex interplay of pathogenic factors complicates management of both diseases.

EPCCS

3' education - Feb. 8, 2019

The cardiovascular challenge for primary care in diabetes

10' education - July 10, 2018 - Prof. Richard Hobbs - Oxford, UK

Consideration of SGLT2 inhibitor treatment in broader T2DM population

3' education - Nov. 26, 2018 - Steve Wiviott, MD - Boston, MA, VS.

CV safety with weight loss agent in high-risk overweight or obese patients

3' education - Aug. 26, 2018 - Dr. Erin Bohula, Boston, MA, US

No overall benefit with aspirin in a primary prevention setting of diabetes patients

3' education - Aug. 27, 2018 - Prof. Jane Armitage, Oxford, UK

Omega-3 fatty acid supplements do not result in CV benefits

3' education - Aug. 26, 2018 - Dr Louise Bowman, Oxford, UK
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (3/3)

Practical management of cardiovascular risk: Lessons from latest diabetes trials

10' education - July 17, 2018 - Prof. Lars Rydén - Stockholm, Sweden
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (2/3)

Diabetes: How to reduce risk from a cardiovascular perspective?

10' education - July 12, 2018 - Prof. Diederick Grobbee - Utrecht, The Netherlands

Management of CV risk that comes with T2DM in light of novel treatment options

10' education - Mar. 15, 2018 - EPCCS 2018, Barcelona, Spain - Dr. Carlos Brotons, prof. Xavier Cos, prof. Richard Hobbs

Striking results for weight reduction in T2DM in primary care based program

3' education - Dec. 18, 2017 - IDF 2017 - Abu Dhabi, UAE - Prof Naveed Sattar, MD - Glasgow, UK

The evidence base for health behaviour changes

10' education - Dec. 9, 2015 - EPCCS 2015 - Prague, Czech Republic

What's the evidence for BP and lipid targets in diabetes?

3' education - Nov. 25, 2014 - EPCCS 2014, Brussels
##SCROLLER_ITEMS_FULL_TITLE##

Future developments in treating hyperglycemia in type 2 diabetes

3' education - Sep. 20, 2013 - London, 5-6 September 2013 - Neil Munro

Efficacy of statins in primary CVD prevention confirmed in large meta-analysis, but individual benefit-harm profiles vary

Literature - Feb. 19, 2019 - Yebyo HG et al. - Am Heart J 2019

This meta-analysis of RCTs on statins demonstrated reduced risk of most CVD outcomes in primary prevention populations, with increased risk of some side effects. A network meta-analysis revealed different benefit-harm profiles for specific statins.

EPCCS

European Primary Care Cardiovascular Society

3' education - Feb. 8, 2019

Learn more about the activities of EPCCS that are aimed at supporting primary care professionals manage their patients with cardiovascular and cardiometabolic disease.

Variation in the magnitude of the association between ideal CV health and lower diabetes risk by glycemic status

Literature - Jan. 24, 2019 - Joseph JJ et al. - Diabetologia 2019

High number of ideal CV health metrics is associated with low incidence of diabetes in subjects with normal fasting glucose, but not in those with impaired fasting glucose.

CV benefit, but higher bleeding with aspirin in primary prevention setting

Literature - Jan. 23, 2019 - Zheng SL, Roddick AJ - JAMA 2019

Use of aspirin resulted in reduction of composite of CV mortality, nonfatal MI and nonfatal stroke in primary prevention setting, shown in a meta-analysis including 13 trials with more than 164.000 individuals, but at the cost of higher risk of major bleeding.

Prediction of individual CVD-free life-years gained and effect of treatment with decision tool in T2DM

Literature - Jan. 21, 2019 - Berkelmans GFN et al. - European Heart Journal 2019

The Diabetes Lifetime-perspective prediction (DIAL) model was developed and can be used in the U-Prevent decision tool to predict individual CVD-free life expectancy and the effect of lifelong treatment on CVD-free life-years gained.

Physical activity reduces mortality in T2DM, thus it needs more attention

News - Jan. 15, 2019

EAPC Position Statement states that exercise programs for diabetics are a cost effective treatment and should be reimbursed

The cardiovascular challenge for primary care in diabetes

10' education - July 10, 2018 - Prof. Richard Hobbs - Oxford, UK
Prof. Hobbs stresses  the importance of CVRM in primary care and how to manage this risk beyond glucose control.

Prof. Hobbs stresses the importance of CVRM in primary care and how to manage this risk beyond glucose control.

Consideration of SGLT2 inhibitor treatment in broader T2DM population

AHA 2018 - Chicago, IL, VS

3' education - Nov. 26, 2018 - Steve Wiviott, MD - Boston, MA, VS.
Dapagliflozin was evaluated in both primary and secondary prevention patients with T2DM. Stephen Wiviott summarizes the results of DECLARE TIMI-58, along with those of a meta-analysis of the 3 SGLT2i CVOTs.

AHA 2018 Dapagliflozin was evaluated in both primary and secondary prevention patients with T2DM. Stephen Wiviott summarizes the results of DECLARE TIMI-58, along with those of a meta-analysis of the 3 SGLT2i CVOTs.

Discovering of more structural brain abnormalities in prediabetes compared to no diabetes

Literature - Nov. 22, 2018 - Van Agtmaal MJM et al. - Diab Care 2018

Structural brain abnormalities are more common in patients with prediabetes compared with non-diabetics, and even more common in T2DM patients.

Lower HF hospitalization with SGLT2 inhibitor in both primary and secondary prevention T2DM patients

AHA 2018 – Chicago, IL, USA

News - Nov. 22, 2018

AHA 2018 Dapagliflozin was associated with a reduction in CVD/hospitalization in T2DM patients with ASCVD or with multiple risk factors, and with a modest decrease in MACE in those with existing ASCVD.

2018 Guidelines on the management of cholesterol: take home messages

News - Nov. 16, 2018

AHA 2018 The American Heart Association (AHA) and the American College of Cardiology (ACC) updated the 2018 cholesterol guidelines. A summary of key recommendations concerning cholesterol management in de prevention of CVD.

Intensive lifestyle intervention program associated with reduced CV risk in overweight/obese adults

Literature - Nov. 9, 2018 - Salas-Salvadó J et al. - Diabetes Care 2018

In this randomized trial, the long-term intensive PREDIMED-Plus lifestyle intervention resulted in weight loss and reduced CV risk in overweight/obese adults with metabolic syndrome, compared to standard care.